Nateglinide (Starlix) is a fast-acting, short-duration meglitinide taken right before each meal to control post-meal glucose in type 2 diabetes. It lowers A1C by about 0.5 to 1.0 percent with less hypoglycemia and weight gain than sulfonylureas. Doses can be skipped if a meal is skipped. Side effects include mild hypoglycemia, upper respiratory infection, and dizziness.
What Nateglinide Is
Nateglinide is a D-phenylalanine derivative classified as a meglitinide — a short-acting insulin secretagogue. The brand name Starlix is manufactured by Novartis; generic nateglinide has been available since 2013. The FDA approved nateglinide in December 2000 for type 2 diabetes.
Meglitinides are sometimes called “glinides” or “prandial insulin secretagogues” because they are designed to be taken with each meal to handle the post-meal glucose rise, in contrast to sulfonylureas which provide steady all-day insulin release.
Who Qualifies
Nateglinide is indicated for adults with type 2 diabetes as monotherapy or in combination with metformin or a thiazolidinedione. It is generally considered when:
- Post-meal glucose excursions drive most of the elevated A1C
- Sulfonylurea hypoglycemia has been a problem
- Meal patterns are irregular (shift work, frequent travel, intermittent fasting protocols)
- Newer agents (DPP-4i, SGLT2i, GLP-1 RA) are not available or contraindicated
Nateglinide is not used in type 1 diabetes or diabetic ketoacidosis.
How It Works
Pancreatic beta cells have ATP-sensitive potassium (K-ATP) channels. When glucose levels rise after a meal, intracellular ATP increases, closing K-ATP channels, depolarizing the cell, and triggering insulin secretion. Sulfonylureas and meglitinides bind directly to K-ATP channels to close them, increasing insulin release.
Nateglinide binds the K-ATP channel with rapid onset and rapid dissociation. The result is:
- Insulin release within 15 minutes
- Peak insulin at about 1 hour
- Return to baseline by 4 hours
This short, sharp insulin response matches the post-meal glucose rise rather than producing prolonged insulin elevation.
Dosing
| Setting | Dose | Timing |
|---|---|---|
| Treatment-naive, near goal A1C | 60 mg three times daily | 1 to 30 min before each meal |
| Standard starting dose | 120 mg three times daily | 1 to 30 min before each meal |
| Skipped meal | Skip the dose | — |
| Renal impairment | No adjustment needed | — |
| Hepatic impairment (mild-moderate) | Use with caution | — |
Nateglinide is generally taken 10 minutes before meals; if a meal is delayed beyond 30 minutes, hold the dose until immediately before eating to avoid hypoglycemia.
Expected Effect on A1C and Glucose
- Average A1C reduction: 0.5 to 1.0 percent
- Reduction in 2-hour post-meal glucose: 40 to 70 mg/dL
- Fasting glucose change: small (about 10 to 20 mg/dL)
- Effect on weight: usually +1 to 2 kg
Nateglinide is more effective at lowering post-meal glucose than fasting glucose, which is why patients with predominantly post-meal hyperglycemia (typical of early type 2 diabetes) often respond best.
The NAVIGATOR Trial
The NAVIGATOR trial randomized 9,306 patients with impaired glucose tolerance (prediabetes) and cardiovascular risk to nateglinide, valsartan, both, or placebo. Nateglinide did not significantly reduce progression to type 2 diabetes at 5 years (36 percent on nateglinide vs 34 percent on placebo). This negative result is one reason meglitinides are not used for diabetes prevention — unlike metformin, which has clear DPP data, or GLP-1 RAs, which have emerging prevention evidence.
Common Side Effects
- Hypoglycemia — less common than with sulfonylureas; typically mild
- Upper respiratory infection — 11%
- Back pain — 4%
- Diarrhea — 3%
- Bronchitis — 3%
- Cough — 3%
- Joint pain
- Dizziness
- Weight gain (small)
Serious Risks
- Hypoglycemia — rare with nateglinide monotherapy but more frequent when combined with insulin or sulfonylureas; older patients and those with reduced food intake are at higher risk
- Hypersensitivity reactions — rare; rash, itching, urticaria
- Hepatic dysfunction — uncommon; transaminase elevation; monitor in patients with liver disease
Contraindications
- Type 1 diabetes
- Diabetic ketoacidosis
- Known hypersensitivity to nateglinide
- Pregnancy (insulin is preferred)
How Nateglinide Compares
| Agent | Class | A1C Reduction | Hypoglycemia Risk | Weight Effect |
|---|---|---|---|---|
| Nateglinide | Meglitinide | 0.5-1.0% | Low-Moderate | +1-2 kg |
| Repaglinide | Meglitinide | 1.0-1.5% | Moderate | +1-3 kg |
| Glipizide | Sulfonylurea | 1.0-2.0% | High | +2-3 kg |
| Glyburide | Sulfonylurea | 1.0-2.0% | Highest | +2-4 kg |
| Metformin | Biguanide | 1.0-1.5% | Very low | Neutral or -1-2 kg |
| Sitagliptin (DPP-4i) | DPP-4 inhibitor | 0.5-0.8% | Very low | Neutral |
| Empagliflozin (SGLT2i) | SGLT2 inhibitor | 0.5-1.0% | Very low | -2-3 kg |
| Semaglutide | GLP-1 RA | 1.0-2.0% | Very low | -3-7 kg |
Where Nateglinide Fits Today
In the 2024 American Diabetes Association Standards of Care, meglitinides are not listed in the preferred algorithm for most patients with type 2 diabetes. The preferred agents are metformin, GLP-1 receptor agonists, and SGLT2 inhibitors, with each guided by cardiovascular, renal, and weight considerations. Meglitinides retain a niche role:
- Patients with very irregular meal patterns
- Patients who tolerate neither sulfonylureas (hypoglycemia, weight gain) nor newer agents (cost, access)
- Mild-to-moderate kidney impairment where sulfonylurea hypoglycemia risk is amplified
- Sulfa allergy where sulfonylureas are avoided
Practical Considerations
- Take 1 to 30 minutes before each meal — closer to the meal is better.
- Skip the dose if you skip a meal.
- Carry a glucose source for occasional hypoglycemia.
- Combine with metformin or other agents for additive A1C benefit.
- Generic nateglinide is reasonably priced compared with brand-name newer agents.
- Check post-meal (2-hour) glucose to assess effect; fasting numbers may underestimate benefit.
Related Reading
For more on this class, see our pieces on repaglinide and the meglitinides drug class. Also see our pillar on treatment options and our explanation of A1C levels.
The Bottom Line
Nateglinide (Starlix) is a short-acting meglitinide taken before each meal to control post-meal glucose rise in type 2 diabetes. It produces about 0.5 to 1.0 percent A1C reduction with lower hypoglycemia and weight-gain risk than sulfonylureas, and doses can be skipped when meals are skipped. Today it is a niche option — used mostly for irregular eaters or patients intolerant of newer agents. The NAVIGATOR trial did not show benefit for diabetes prevention in prediabetes. Talk to your doctor about whether nateglinide fits your eating pattern and overall diabetes plan.
